Art. -Nr.: HY-N2000

Bellidifolin

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.74%
CAS. Nr.: 2798-25-6
Formel: C₁₄H₁₀O₆
Molecular Weight:274.23

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Bellidifolin Chemical Structure

CAS. Nr.: 2798-25-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

STAT3

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
C6	IC₅₀	>100 μM Compound: 7	Antiproliferative activity against rat C6 cells assessed as cell number after 48 hrs by crystal violet assay Antiproliferative activity against rat C6 cells assessed as cell number after 48 hrs by crystal violet assay	[PMID: 18406151]
U-251	IC₅₀	>100 μM Compound: 7	Antiproliferative activity against human U251 cells assessed as cell number after 48 hrs by crystal violet assay Antiproliferative activity against human U251 cells assessed as cell number after 48 hrs by crystal violet assay	[PMID: 18406151]

In Vitro

Bellidifolin (25-100 μM; 72 h) potently inhibits the proliferation of human A549 lung adenocarcinoma cells in a concentration-dependent manner after 72 h, with significant inhibitory effects observed at concentrations of 50, 75, and 100 μM; however, it exerts no antiproliferative activity against normal human lung epithelial BEAS-2b cells following treatment at 25 to 100 μM for 72 h^[1].
Bellidifolin (50-100 μM; 72 h) upregulates the levels of caspase-8 and caspase-3 in a dose-dependent manner, and downregulates the level of PARP1, in human A549 lung adenocarcinoma cells^[1].
Bellidifolin (10-40 μM; pre-incubated for 4 h followed by 6 h of hypoxia treatment) concentration-dependently ameliorates hypoxia-induced morphological damage in PC12 cells, with the 40 μM concentration enabling near-complete recovery of cell morphology to the normal state^[2].
Bellidifolin (with BRD4 overexpressed, pre-incubated for 0.5 h prior to 12 h of ISO stimulation, at an administration concentration of 30 μM) exerts anti-hypertrophic effects, restores cell viability, and inhibits ISO-stimulated Pol II phosphorylation in H9C2 cells in a BRD4-dependent manner^[3].
Bellidifolin (administered following 0.5 h of pre-incubation, followed by ISO stimulation for 12 h, and conducted after Nox4 overexpression/knockdown and BRD4 overexpression) inhibits ISO-induced cardiomyocyte hypertrophy in H9C2 cells via a BRD4/Nox4-dependent pathway^[3].
Bellidifolin (10 μM; 2 h pre-incubation) restores reduced anti-adipogenic protein levels in HepG2 cells, activates AMPK and inhibits mTOR phosphorylation, thereby reversing the BPF-induced upregulation of adipogenesis-related mRNAs and proteins, restoring the dysregulated AMPK-mTOR signaling axis, and suppressing the translocation of SREBP-1c from the cytoplasm to the nucleus^[4].
Bellidifolin (12.5-50 μM; 24 h) reduces the expression levels of TGF-β1-induced α-SMA, Collagen I and Collagen III proteins, and inhibits TGF-β1-induced SOX9 expression and Smad3 phosphorylation in human cardiac fibroblasts^[5].
Bellidifolin (20-80 μM; 12 h) alters the gene expression of H9c2 cells subjected to H₂O₂-induced injury, with its differentially expressed genes (DEGs) enriched in pathways including the PI3K-Akt signaling pathway^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

human A549 lung adenocarcinoma cells, human normal lung epithelial BEAS-2b cells
Concentration:

25 μM, 50 μM, 75 μM, 100 μM
Incubation Time:

72 h
Result:

Exhibited a time- and concentration-dependent inhibitory effect on proliferation in A549 cells, with significantly more evident growth inhibition at 50, 75, and 100 μM compared to 25 μM.
Caused no cytotoxic or antiproliferative effect in BEAS-2b cells at 25, 50, 75, and 100 μM.

Cell Viability Assay^[2]

Cell Line:

pheochromocytoma (PC12) cells
Concentration:

10-40 μM (pre-incubated)
Incubation Time:

4 h (pre-incubation); 6 h (hypoxia exposure)
Result:

Significantly increased PC12 cell viability to 70.28 ± 4.00% compared to hypoxia alone at 20 μM.
Restored cell viability to near-control levels (85.30 ± 2.45%), which was significantly elevated compared to hypoxia alone, at 40 μM.

Western Blot Analysis^[5]

Cell Line:

TGF-β1-stimulated human cardiac fibroblasts (HCFs)
Concentration:

12.5-50 μM (co-incubated with TGF-β1)
Incubation Time:

24 h
Result:

Significantly downregulated the TGF-β1-induced increases in α-SMA, Collagen I, and Collagen III protein expression.\nPrevented TGF-β1-induced elevations in SOX9 protein expression.
Reduced TGF-β1-induced Smad3 phosphorylation.

In Vivo

Bellidifolin exerts significant protective effects against focal cerebral ischemic injury in rats by inhibiting oxidative stress, reducing excitatory amino acid levels, and increasing GABA content^[2].
Bellidifolin (30 mg/kg/day; p.o.; daily; 21 consecutive days) ameliorates isoprenaline-induced cardiac hypertrophy in Kunming mice by inhibiting the BRD4/Nox4/ROS signalling pathway, significantly reducing cardiac hypertrophy markers, pathological changes, and restoring cardiac function^[3].
Bellidifolin (100 mg/kg body weight; i.p.; once daily; 14 days) mitigates BPF-induced nonalcoholic fatty liver disease-like changes in male C57BL/6J mice by activating AMPK, inhibiting mTOR, and downregulating lipogenesis-associated proteins^[4].
Bellidifolin (25-50 mg/kg; p.o.; daily; 21 days) ameliorates isoproterenol-induced myocardial fibrosis in Kunming mice by inhibiting SOX9 expression, which in turn reduces the expression of α-SMA, Collagen I, and Collagen III^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (male, 8-10 weeks old, 18-22 g, isoprenaline-induced cardiac hypertrophy)^[3]
Dosage:

30 mg/kg/day
Administration:

p.o.; daily; 21 consecutive days
Result:

Significantly reduced increases in ejection fraction (EF) and fractional shortening (FS).
Reversed increases in left ventricular diastolic anterior wall thickness (LVAWd) and left ventricular systolic anterior wall thickness (LVAWs).
Increased left ventricular end-systolic diameter (LVESD).
Reduced cardiomyocyte disarray, collagen deposition, and cardiomyocyte cross-sectional area.
Significantly decreased protein levels of ANP and BNP, and mRNA levels of ANP, BNP, and β-MHC.
Reduced isoprenaline-induced elevation of BRD4 protein and mRNA levels.
Decreased H3K122 acetylation and RNA Pol II phosphorylation.
Reduced Nox4 protein and mRNA levels, decreased intracellular ROS levels, and reduced mRNA levels of ADAM17 and TNF-α.

Animal Model:

C57BL/6J (male, 5 to 6 weeks old, NAFLD induced by bisphenol F gavage)^[4]
Dosage:

100 mg/kg body weight
Administration:

i.p.; once daily; 14 days
Result:

Significantly reduced BPF-induced hepatic lipid deposition, as shown by decreased Oil Red O staining intensity.
Normalized BPF-increased liver triglyceride and total cholesterol levels.
Reversed BPF-induced upregulation of lipogenesis-associated proteins (ACC, FAS, SREBP-1c, C/EBPα, PPARγ, SCD1) in mouse liver.
Restored BPF-reduced AMPK phosphorylation and inhibited BPF-increased mTOR phosphorylation in mouse liver.

Animal Model:

Kunming (male; isoproterenol-induced myocardial fibrosis model)^[5]
Dosage:

25 mg/kg; 50 mg/kg
Administration:

p.o.; daily; 21 days
Result:

Significantly improved ISO-induced histopathological myocardial changes, including reducing myocardial fiber disorganization, degeneration, necrosis, and inflammatory cell infiltration.
Significantly reduced ISO-induced collagen deposition in cardiac tissue.
Prevented ISO-induced elevations in the fibrosis-related proteins α-SMA, Collagen I, and Collagen III, as measured by Western blot and immunohistochemistry.
Significantly decreased ISO-induced increases in SOX9 protein expression in cardiac tissue.
Achieved statistically significant reductions relative to the ISO model group for all measured endpoints.

Chemical Information

CAS. Nr. 2798-25-6
Appearance Solid
Molecular Weight 274.23
Formel C₁₄H₁₀O₆
Color Light yellow to yellow
SMILES

O=C1C2=C(OC3=C1C(O)=CC=C3O)C=C(OC)C=C2O
Structure Classification
- Phenols
- Polyphenols
- Phenols
- Xanthones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Biomed Eng

2026 Apr 24. PMID: 42032039
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (182.33 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6466 mL

18.2329 mL

36.4657 mL

5 mM

0.7293 mL

3.6466 mL

7.2931 mL

10 mM

0.3647 mL

1.8233 mL

3.6466 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Woo SY, et al. Viral protein R inhibitors from Swertia chirata of Myanmar. J Biosci Bioeng. 2019 May 7.

[2]. Yan L, et al. Bellidifolin Inhibits Proliferation of A549 Cells by Regulating STAT3/COX-2 Expression and Protein Activity. J Oncol. 2020 Nov 21;2020:1723791. [Content Brief]

[3]. Zhao ZY, et al. Protective effects of bellidifolin in hypoxia-induced in pheochromocytoma cells (PC12) and underlying mechanisms. J Toxicol Environ Health A. 2017;80(22):1187-1192. [Content Brief]

[4]. Zhou D, et al. Bellidifolin ameliorates isoprenaline-induced cardiac hypertrophy by the Nox4/ROS signalling pathway through inhibiting BRD4. Cell Death Discov. 2023;9(1):279. Published 2023 Aug 1. [Content Brief]

[5]. Xue J, et al. A novel bellidifolin intervention mitigates nonalcoholic fatty liver disease-like changes induced by bisphenol F. J Biomed Res. 2024;38(5):451-463. [Content Brief]

[6]. Yao TT, et al. Bellidifolin Inhibits SRY-Related High Mobility Group-Box Gene 9 to Block TGF-β Signalling Activation to Ameliorate Myocardial Fibrosis. Evid Based Complement Alternat Med. 2022 May 9;2022:6841276. [Content Brief]

[7]. Li S, et al. Bellidifolin from Gentianella acuta (Michx.) Hulten protects H9c2 cells from hydrogen peroxide-induced injury via the PI3K-Akt signal pathway. Toxicol Rep. 2022 Aug 17;9:1655-1665. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6466 mL	18.2329 mL	36.4657 mL	91.1643 mL
	5 mM	0.7293 mL	3.6466 mL	7.2931 mL	18.2329 mL
	10 mM	0.3647 mL	1.8233 mL	3.6466 mL	9.1164 mL
	15 mM	0.2431 mL	1.2155 mL	2.4310 mL	6.0776 mL
	20 mM	0.1823 mL	0.9116 mL	1.8233 mL	4.5582 mL
	25 mM	0.1459 mL	0.7293 mL	1.4586 mL	3.6466 mL
	30 mM	0.1216 mL	0.6078 mL	1.2155 mL	3.0388 mL
	40 mM	0.0912 mL	0.4558 mL	0.9116 mL	2.2791 mL
	50 mM	0.0729 mL	0.3647 mL	0.7293 mL	1.8233 mL
	60 mM	0.0608 mL	0.3039 mL	0.6078 mL	1.5194 mL
	80 mM	0.0456 mL	0.2279 mL	0.4558 mL	1.1396 mL
	100 mM	0.0365 mL	0.1823 mL	0.3647 mL	0.9116 mL

Keywords

Bellidifolin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bellidifolin

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Bellidifolin

Alle STAT Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bellidifolin Related Classifications

Art. -Nr.: HY-N2000